This white paper summarizes current evidence supporting the use of fractional exhaled nitric oxide (FeNO) to aid in the initial diagnosis and routine management of asthma. The clinical benefits of measuring and monitoring FeNO in asthma are well recognized and FeNO testing is currently recommended by all key international and national asthma guidelines.
Our publications and whitepapers cover FeNO and why you should use it for asthma diagnosis and management. Explore today.
NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma.
NIOX VERO® provides accurate and reliable results, allowing healthcare professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, with a simple touch screen interface and intuitive design, and can be used in a variety of settings, including clinics, hospitals, and primary care settings.
The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals.
Overall, NIOX Group plc is the global leader in FeNO testing, with a strong reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive1 tool to help them better diagnose and manage asthma.
